These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15609120)

  • 21. The Danish health care system: evolution--not revolution--in a decentralized system.
    Pedersen KM; Christiansen T; Bech M
    Health Econ; 2005 Sep; 14(Suppl 1):S41-57. PubMed ID: 16170792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does drug price-regulation affect healthcare expenditures?
    Ben-Aharon O; Shavit O; Magnezi R
    Eur J Health Econ; 2017 Sep; 18(7):859-867. PubMed ID: 27696009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pricing and reimbursement of pharmaceuticals in Italy.
    Folino-Gallo P; Montilla S; Bruzzone M; Martini N
    Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden. Assessment of models for decentralized financing of subsidies from a management perspective.
    Bergström G; Karlberg I
    Health Policy; 2007 May; 81(2-3):358-67. PubMed ID: 16942815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis.
    Garattini L; Cornago D; De Compadri P
    Health Policy; 2007 Aug; 82(3):330-9. PubMed ID: 17125881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost sharing for pharmaceuticals--the Swedish reimbursement system.
    Jönsson B
    Pharmacoeconomics; 1996; 10 Suppl 2():68-74. PubMed ID: 10163438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The economic burden of prescription drug use among elderly patients in Ponce, Puerto Rico.
    López-Negrón L; Monsanto-Planadeball HA
    P R Health Sci J; 2006 Jun; 25(2):149-53. PubMed ID: 17203713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medicare program; changes to the hospital inpatient prospective payment systems and fiscal year 2007 rates; fiscal year 2007 occupational mix adjustment to wage index; health care infrastructure improvement program; selection criteria of loan program for qualifying hospitals engaged in cancer-related health care and forgiveness of indebtedness; and exclusion of vendor purchases made under the competitive acquisition program (CAP) for outpatient drugs and biologicals under part B for the purpose of calculating the average sales price (ASP). Final rules and interim final rule with comment period.
    Centers for Medicare and Medicaid Services (CMS), HHS
    Fed Regist; 2006 Aug; 71(160):47869-8351. PubMed ID: 16921666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is there a business case for quality in The Netherlands? A critical analysis of the recent reforms of the health care system.
    Custers T; Arah OA; Klazinga NS
    Health Policy; 2007 Jul; 82(2):226-39. PubMed ID: 17070956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative strategies for Medicare payment of outpatient prescription drugs--Part B and beyond.
    Danzon PM; Wilensky GR; Means KE
    Am J Manag Care; 2005 Mar; 11(3):173-80. PubMed ID: 15786856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in prescribing behaviors after implementing drug reimbursement rate reduction policy in Taiwan: implications for the medicare system.
    Chu HL; Liu SZ; Romeis JC
    J Health Care Finance; 2008; 34(3):45-54. PubMed ID: 18468378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Swedish healthcare under pressure.
    Anell A
    Health Econ; 2005 Sep; 14(Suppl 1):S237-54. PubMed ID: 16161198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmaceutical Pricing and Reimbursement in Japan: For Faster, More Complete Access to New Drugs.
    Takayama A; Narukawa M
    Ther Innov Regul Sci; 2016 May; 50(3):361-367. PubMed ID: 30227073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Drug evaluation by the French National Health Authority for reimbursement decisions].
    Bouvenot G
    Bull Acad Natl Med; 2005 Nov; 189(8):1683-90; discussion 1690-1. PubMed ID: 16737094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and implementation of health technology assessment in Argentina: two steps forward and one step back.
    Rubinstein A; Pichon-Riviere A; Augustovski F
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():260-9. PubMed ID: 19527545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Changes of drug reimbursement expenses incurred by National Health Fund in Silesian voivodeship in the period of 1999-2004].
    Swistak P; Dzielicki M; Janiec R; Błońska-Fajfrowska B
    Wiad Lek; 2005; 58(9-10):495-9. PubMed ID: 16529058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic aspects of the new Spanish laws on pharmaceutical preparations.
    Antoñanzas F; Oliva J; Pinillos M; Juàrez C
    Eur J Health Econ; 2007 Sep; 8(3):297-300. PubMed ID: 17401592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Future and implications of reimbursement for obesity treatment.
    Stern JS; Kazaks A; Downey M
    J Am Diet Assoc; 2005 May; 105(5 Suppl 1):S104-9. PubMed ID: 15867905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The strategic interaction between firms and formulary committees: effects on the prices of new drugs.
    García-Alonso MD; García-Mariñoso B
    J Health Econ; 2008 Mar; 27(2):377-404. PubMed ID: 18276026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.